Lancashire and South Cumbria Formulary

Formulary Chapter 4: Central nervous system - Full Section

04.01

Hypnotics and anxiolytics (0,0)

04.01.01

Non-benzodiazepine hypnotics and sedatives (6,0)

Benzodiazepines (5,0)

Chloral and derivatives (1,0)

Antihistamines (2,0)

Alcohol (0,0)

Sodium oxybate (1,0)

04.01.02

Anxiolytics (2,0)

Benzodiazepines (8,0)

Beta blockers (1,0)

Meprobamate (1,0)

04.02

Drugs used in psychoses and related disorders (0,0)

First-Generation Antipsychotic Drugs (10,0)

Second-Generation Antipsychotic Drugs (9,0)

04.02.02

Antipsychotic depot injections (8,0)

04.02.03

Drugs used for mania and hypomania (1,0)

Benzodiazepines (1,0)

Antipsychotic drugs (0,0)

Carbamazepine (1,0)

Valproic acid (2,0)

Lithium (3,0)

04.03

Antidepressant drugs (0,0)

04.03.01

Tricyclic and related antidepressant drugs (0,0)

Tricyclic antidepressants (8,0)

Related antidepressants (1,0)

04.03.02

Monoamine-oxidase inhibitors (1,0)

Reversible MAOIs (1,0)

04.03.03

Selective serotonin re-uptake inhibitors (6,0)

04.03.04

Other antidepressant drugs (5,0)

04.03.05

Tetracyclic antidepressants (2,0)

04.04

CNS stimulants and other drugs used for attention deficit hyperactivity disorder (8,0)

Cocaine (0,0)

04.05

Drugs used in the treatment of obesity (0,0)

04.05.01

Anti-obesity drugs acting on the gastro-intestinal tract (4,0)

04.05.02

Centrally acting appetite suppressants (1,0)

04.06

Drugs used in nausea and vertigo (0,0)

Vomiting during pregnancy (0,0)

Postoperative nausea and vomiting (0,0)

Motion sickness (0,0)

Other vestibular disorders (0,0)

Cytotoxic chemotherapy (1,0)

Palliative care (0,0)

Migraine (0,0)

Antihistamines (4,0)

Phenothiazines and related drugs (3,0)

Domperidone and metoclopramide (2,0)

5HT3 antagonists (3,0)

Neurokinin receptor antagonist (2,0)

Hyoscine (1,0)

Other drugs for Ménière's disease (1,0)

04.07

Analgesics (1,0)

04.07.01

Non-opioid analgesics and compound analgesic preparations (3,0)

04.07.02

Opioid analgesics (13,0)

04.07.03

Neuropathic pain (7,0)

Trigeminal neuralgia (1,0)

Chronic facial pain (0,0)

NMDA receptor antagonists (0,0)

04.07.04

Antimigraine drugs (0,0)

04.07.04.01

Treatment of the acute migraine attack (0,0)

5HT1 agonists (2,0)

Anti-emetics (0,0)

04.07.04.02

Prophylaxis of migraine (13,0)

04.08

Antiepileptics (0,0)

04.08.01

Control of epilepsy (3,0)

Partial seizures with or without secondary generalisation (0,0)

Generalised seizures (0,0)

Carbamazepine and Oxcarbazepine (3,0)

Ethosuximide (1,0)

Gabapentin and pregabalin (2,0)

Lacosamide (2,0)

Lamotrigine (1,0)

Levetiracetam (2,0)

Perampanel (1,0)

Phenobarbital and other barbiturates (2,0)

Phenytoin (1,0)

Retigaine (0,0)

Rufinamide (1,0)

Rufinamide (0,0)

Tiagabine (1,0)

Topiramate (1,0)

Valproate (2,0)

Vigabatrin (1,0)

Zonisamide (1,0)

Benzodiazepines (1,0)

Other Drugs (2,0)

04.08.02

Drugs used in status epilepticus (7,0)

04.09

Drugs used in parkinsonism and related disorders (0,0)

Dopamine receptor agonists (8,0)

Levodopa (6,0)

Monoamine-oxidase-B inhibitors (2,0)

Catachol-O-methyltransferase inhibitors (3,0)

Amantadine (0,0)

04.09.02

Antimuscarinic drugs used in parkinsonism (5,0)

04.09.03

Drugs used in essential tremor, chorea, tics, and related disorders (5,0)

Torsion dystonias and other involuntary movements (2,0)

04.09.04

Restless leg syndrome (0,0)

04.10

Drugs used in substance dependence (0,0)

Alcohol dependence (0,0)

Cigarette smoking (1,0)

04.10.01

Alcohol dependence (2,0)

04.10.02

Nicotine dependence (1,0)

04.10.03

Opioid dependence (1,0)

Opioid substitution therapy (3,0)

Adjunctive therapy and symptomatic treatment (1,0)

Opioid-receptor antagonists (1,0)

04.11

Drugs for dementia (4,0)

04.12

Other Nervous System medicines (2,0)